Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
72
RIGL Quote, Financials, Valuation and Earnings
Last price:
$41.63
Seasonality move
:
-1.35%
Day range:
$41.58 - $43.56
52-week range:
$14.63 - $52.24
Dividend yield:
0%
P/E ratio:
6.74x
P/S ratio:
2.71x
P/B ratio:
6.42x
Volume:
1.4M
Avg. volume:
632K
1-year change:
141.66%
Market cap:
$754.9M
Revenue:
$179.3M
EPS (TTM):
$6.17
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$59.3M | $0.80 | 15.36% | 30.92% | $49.60 |
|
CATX
Perspective Therapeutics, Inc.
|
$147K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$142.4M | $0.59 | -0.23% | 4.65% | $34.86 |
|
FOLD
Amicus Therapeutics, Inc.
|
$162.3M | $0.09 | 20.07% | 224.54% | $15.25 |
|
LLY
Eli Lilly & Co.
|
$17B | $7.46 | 31.31% | 54.32% | $1,093.22 |
|
NKTR
Nektar Therapeutics
|
$10.1M | -$2.59 | -64.22% | -1474.64% | $114.43 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$41.59 | $49.60 | $754.9M | 6.74x | $0.00 | 0% | 2.71x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.7500 | $12.3077 | $204.4M | -- | $0.00 | 0% | 186.46x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$23.74 | $34.86 | $2.9B | 13.85x | $0.00 | 0% | 5.21x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.18 | $15.25 | $4.4B | -- | $0.00 | 0% | 7.26x |
|
LLY
Eli Lilly & Co.
|
$1,071.44 | $1,093.22 | $959B | 52.99x | $1.50 | 0.56% | 16.44x |
|
NKTR
Nektar Therapeutics
|
$46.84 | $114.43 | $810.4M | -- | $0.00 | 0% | 48.30x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RIGL
Rigel Pharmaceuticals, Inc.
|
34.11% | 2.066 | 11.84% | 1.94x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
0.31% | -0.528 | 0.12% | 6.19x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | 0.379 | 18.22% | 1.91x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.293 | 6.22% | 0.65x |
|
NKTR
Nektar Therapeutics
|
66.26% | 7.157 | 16.97% | 4.07x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$64.7M | $28.4M | 111.09% | 273.99% | 40.92% | $24M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$116.4M | $66.3M | 27.37% | 27.48% | 44.66% | $32.4M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
NKTR
Nektar Therapeutics
|
$11.6M | -$31.5M | -54.14% | -327.67% | -267.45% | -$48.9M |
Rigel Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns RIGL or CATX?
Perspective Therapeutics, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of -12425.36%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital RIGLRigel Pharmaceuticals, Inc.93.16% $1.46 $178.5M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About RIGL or CATX?
Rigel Pharmaceuticals, Inc. has a consensus price target of $49.60, signalling upside risk potential of 19.26%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 347.55%. Given that Perspective Therapeutics, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Rigel Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RIGLRigel Pharmaceuticals, Inc.3 2 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is RIGL or CATX More Risky?
Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.026% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock RIGL or CATX?
Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RIGL or CATX?
Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 6.74x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.71x versus 186.46x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RIGLRigel Pharmaceuticals, Inc.2.71x 6.74x $69.5M $27.9M CATXPerspective Therapeutics, Inc.186.46x -- $209K -$26M
-
Which has Higher Returns RIGL or CPRX?
Catalyst Pharmaceuticals, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 35.57%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.
Company Gross Margin Earnings Per Share Invested Capital RIGLRigel Pharmaceuticals, Inc.93.16% $1.46 $178.5M CPRXCatalyst Pharmaceuticals, Inc.78.44% $0.42 $923.1M -
What do Analysts Say About RIGL or CPRX?
Rigel Pharmaceuticals, Inc. has a consensus price target of $49.60, signalling upside risk potential of 19.26%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.86 which suggests that it could grow by 46.83%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Rigel Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RIGLRigel Pharmaceuticals, Inc.3 2 0 CPRXCatalyst Pharmaceuticals, Inc.6 0 0 -
Is RIGL or CPRX More Risky?
Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.026% more volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.5%.
-
Which is a Better Dividend Stock RIGL or CPRX?
Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RIGL or CPRX?
Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 6.74x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 13.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.71x versus 5.21x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RIGLRigel Pharmaceuticals, Inc.2.71x 6.74x $69.5M $27.9M CPRXCatalyst Pharmaceuticals, Inc.5.21x 13.85x $148.4M $52.8M
-
Which has Higher Returns RIGL or FOLD?
Amicus Therapeutics, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 10.24%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital RIGLRigel Pharmaceuticals, Inc.93.16% $1.46 $178.5M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About RIGL or FOLD?
Rigel Pharmaceuticals, Inc. has a consensus price target of $49.60, signalling upside risk potential of 19.26%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 8.67%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RIGLRigel Pharmaceuticals, Inc.3 2 0 FOLDAmicus Therapeutics, Inc.3 4 0 -
Is RIGL or FOLD More Risky?
Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.026% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.
-
Which is a Better Dividend Stock RIGL or FOLD?
Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RIGL or FOLD?
Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 6.74x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.71x versus 7.26x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RIGLRigel Pharmaceuticals, Inc.2.71x 6.74x $69.5M $27.9M FOLDAmicus Therapeutics, Inc.7.26x -- $169.1M $17.3M
-
Which has Higher Returns RIGL or LLY?
Eli Lilly & Co. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 31.72%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital RIGLRigel Pharmaceuticals, Inc.93.16% $1.46 $178.5M LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About RIGL or LLY?
Rigel Pharmaceuticals, Inc. has a consensus price target of $49.60, signalling upside risk potential of 19.26%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 2.03%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings RIGLRigel Pharmaceuticals, Inc.3 2 0 LLYEli Lilly & Co.18 7 0 -
Is RIGL or LLY More Risky?
Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.026% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.
-
Which is a Better Dividend Stock RIGL or LLY?
Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RIGL or LLY?
Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 6.74x while Eli Lilly & Co.'s PE ratio is 52.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.71x versus 16.44x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RIGLRigel Pharmaceuticals, Inc.2.71x 6.74x $69.5M $27.9M LLYEli Lilly & Co.16.44x 52.99x $17.6B $5.6B
-
Which has Higher Returns RIGL or NKTR?
Nektar Therapeutics has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of -301.29%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Nektar Therapeutics's return on equity of -327.67%.
Company Gross Margin Earnings Per Share Invested Capital RIGLRigel Pharmaceuticals, Inc.93.16% $1.46 $178.5M NKTRNektar Therapeutics98.34% -$1.87 $252.2M -
What do Analysts Say About RIGL or NKTR?
Rigel Pharmaceuticals, Inc. has a consensus price target of $49.60, signalling upside risk potential of 19.26%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 144.3%. Given that Nektar Therapeutics has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Rigel Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RIGLRigel Pharmaceuticals, Inc.3 2 0 NKTRNektar Therapeutics6 1 0 -
Is RIGL or NKTR More Risky?
Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.026% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.844%.
-
Which is a Better Dividend Stock RIGL or NKTR?
Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RIGL or NKTR?
Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 6.74x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.71x versus 48.30x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RIGLRigel Pharmaceuticals, Inc.2.71x 6.74x $69.5M $27.9M NKTRNektar Therapeutics48.30x -- $11.8M -$35.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
